Gilead Sciences is buying cancer treatment company Forty Seven in a deal valued at approximately $4.9 billion. AP
Gilead Sciences is buying cancer treatment company Forty Seven in a deal valued at approximately $4.9 billion. AP
Gilead acquires Forty Seven for $4.9bn as it eyes expansion into cancer treatment
The deal with Forty Seven complements Gilead's 2017 acquisition of Kite Pharma
